Dear WeFunder Champions,
After our successful convertible debt round on WeFunder, thanks to you, we decided try another crowdfunding platform for a priced round. On October 11th, we launched a priced round (~$70M Pre-Money Valuation) on StartEngine at $7.35/share, $294 minimum. In addition, we recently kicked off our Institutional Investor round with the combined goal of raising up to $10M to fund our 2023 plan. Here is our most recent deck. Our StartEngine campaign ends in January and we are looking forward to re-engaging with our partners at WeFunder to plan our next round of financing.
In an unprecedented move, Pfizer taps tiny biotech company, Clear Creek Bio, for next-gen Covid treatment, as consumers and physicians turn away from Paxlovid. Pfizer’s repurposed, anti-HIV combination product - Paxlovid, has become a big moneymaker for Pfizer this year, projecting $22 billion in sales on the year.
On the darker side, doubling down on a second anti-viral, when COVID’s inflammatory response is the devastating culprit, exposes Pfizer to continued risk, especially with consumers. On the brighter side, this very public pivot by Pfizer, opens up the opportunity for Sen-Jam Pharmaceutical to partner with Pfizer's competitors. Sen-Jam is developing a fast to market (Phase 2), FDA submission ready (May 2023), effective anti-inflammatory that will gain consumer and physician support, which will be easily accessible globally, is the diamond in the rough for the prevention and treatment of Acute COVID and Long COVID.
The research community is realizing the benefit of Sen-Jam’s COVID therapeutic. Researchers highlighted in a Forbes article that appeared over the weekend, provide another sound scientific thesis for using Sen-Jam’s therapeutic for preventing and treating Long Covid.
Sen-Jam just completed another Northeastern University sponsorship program consisting of 25+ future Regulatory Affairs Executives. We invite you to witness the excitement and conviction exhibited by the students working on our COVID therapeutic for Emergency Use Authorization.
We need your help!
“We ALL need this!” That’s the resounding exultation we receive from scientists, doctors, researchers and consumers. We are so close to bringing our products into the spotlight and with over 4M$ raised to date, we are proud of and committed to our investor’s who have joined our mission of safe pharmaceuticals, accessible to all and driving health equality.
Be well, safe, and inspired,
Jim
Ps. Below is our COVID-19 therapeutic DOB 12/6/22 manufactured by KVK Tech. We will begin FDA Submission batches in the coming weeks.
